Cargando…
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC). The role of older agents was underattended over the last years. This study presents the combination of Mitomycin C and Vinorelbine in pretreate...
Autores principales: | Babiak, A, Hetzel, J, Godde, F, König, H-H, Pietsch, M, Hetzel, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360135/ https://www.ncbi.nlm.nih.gov/pubmed/17353918 http://dx.doi.org/10.1038/sj.bjc.6603683 |
Ejemplares similares
-
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012) -
A Phase II Study of Vinorelbine, Mitomycin C and Cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Kwon, Mi Ran, et al.
Publicado: (2002) -
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
por: Chew, Helen Kent, et al.
Publicado: (2014) -
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008) -
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
por: Iaffaioli, R. V., et al.
Publicado: (1995)